C-Peptide: Drugs That Distort This Test

What C-Peptide Measures and Why It Matters

C-peptide (connecting peptide) is a 31-amino-acid fragment released in a 1:1 molar ratio with insulin when proinsulin is cleaved inside pancreatic beta cells. Because it has a longer half-life than insulin (20 to 30 minutes vs. 3 to 5 minutes) and is not extracted by the liver on first pass, C-peptide gives a more stable window into how much insulin the pancreas is actually producing [1].

Clinical Uses

Clinicians order this test for three main reasons. First, it distinguishes type 1 diabetes (low or absent C-peptide) from type 2 diabetes (normal or elevated C-peptide) when the diagnosis is unclear [2]. Second, it evaluates the cause of hypoglycemia: a high C-peptide during low blood glucose suggests an insulinoma or sulfonylurea use, while a suppressed C-peptide points toward exogenous insulin [3]. Third, it tracks residual beta-cell function over time in patients with type 1 diabetes, which has direct implications for therapy intensity and complication risk.

Reference Ranges

Most laboratories report a fasting C-peptide reference range of 0.8 to 3.1 ng/mL (0.26 to 1.03 nmol/L). The American Diabetes Association notes that a stimulated C-peptide below 0.2 nmol/L strongly supports absolute insulin deficiency [2]. Non-fasting or post-meal values run two to three times higher than fasting levels, so the fed/fasted state at the time of the draw is a common source of misinterpretation before any drug effect is even considered.

Drugs That Falsely Raise C-Peptide

Several medication classes stimulate endogenous insulin release or increase insulin demand, both of which inflate C-peptide. A result that looks "reassuringly normal" might simply reflect pharmacologic stimulation rather than healthy beta-cell reserve.

Sulfonylureas

Glipizide, glyburide, and glimepiride bind the SUR1 receptor on beta cells and force insulin (and therefore C-peptide) secretion regardless of ambient glucose. In a study of 40 patients with type 2 diabetes, glyburide 10 mg daily increased fasting C-peptide by a mean of 38% over baseline within four weeks [4]. This is the most clinically significant drug confounder when evaluating unexplained hypoglycemia. A sulfonylurea screen in blood or urine should accompany every C-peptide drawn for hypoglycemia workup [3].

Meglitinides

Repaglinide and nateglinide act on the same potassium channel as sulfonylureas but with a shorter duration. They raise C-peptide in a meal-dependent pattern. A single 120 mg dose of nateglinide increased peak C-peptide by roughly 30% in a crossover pharmacodynamic trial [5]. Because the effect wears off within hours, the timing of the last dose relative to the blood draw matters more than it does with long-acting sulfonylureas.

GLP-1 Receptor Agonists

Semaglutide, liraglutide, dulaglutide, and tirzepatide amplify glucose-dependent insulin secretion by activating the GLP-1 receptor on beta cells. In the SUSTAIN-1 trial (N=388), semaglutide 1.0 mg weekly increased the HOMA-B index (a surrogate for beta-cell output) by approximately 30% at 30 weeks compared to placebo [6]. C-peptide rises as a downstream effect. Because the stimulation is glucose-dependent, the magnitude is smaller when fasting glucose is already low, but clinicians should still note active GLP-1 therapy on the lab requisition.

Corticosteroids

Prednisone, dexamethasone, and methylprednisolone drive insulin resistance through hepatic gluconeogenesis and peripheral glucose uptake impairment. The pancreas compensates by secreting more insulin, raising C-peptide. A National Institutes of Health review documented that even short-course dexamethasone (4 mg for four days) elevated fasting C-peptide by 15 to 25% in healthy volunteers [7]. In patients with limited beta-cell reserve, the rise may be blunted or absent, making the confounder less pronounced but also less predictable.

DPP-4 Inhibitors

Sitagliptin, saxagliptin, linagliptin, and alogliptin block the enzyme that degrades endogenous GLP-1 and GIP. The incretin-mediated insulin boost is more modest than with injected GLP-1 agonists. A 12-week trial of sitagliptin 100 mg showed a mean C-peptide increase of 12% from baseline in treatment-naive type 2 diabetes patients [8]. The clinical relevance is lower, but in borderline cases (such as distinguishing LADA from type 2 diabetes) even a 12% shift can change the interpretation.

Drugs That Falsely Lower C-Peptide

A misleadingly low C-peptide can trigger unnecessary workups for autoimmune diabetes or prompt premature initiation of insulin in a patient who still has adequate beta-cell function.

Exogenous Insulin

This is the single most important drug interaction for C-peptide interpretation. Injected insulin (glargine, detemir, degludec, lispro, aspart) suppresses endogenous insulin secretion through negative feedback on the beta cell. C-peptide drops accordingly. In patients on basal-bolus regimens, fasting C-peptide may fall below 0.5 ng/mL even when substantial beta-cell mass remains [9]. Drawing C-peptide during a structured insulin withdrawal (when safe) or using a glucagon stimulation test can unmask residual secretion that steady-state insulin therapy hides [10].

Somatostatin Analogs

Octreotide and lanreotide, used for acromegaly and neuroendocrine tumors, directly inhibit insulin release from beta cells. Octreotide LAR can reduce C-peptide by 40 to 60% depending on dose [11]. Clinicians ordering C-peptide in patients on somatostatin analogs should document the drug, the dose, and the interval since last injection.

Diazoxide

Diazoxide opens potassium channels on beta cells (the opposite mechanism of sulfonylureas) and suppresses insulin release. It is used therapeutically for hyperinsulinemic hypoglycemia. Patients on diazoxide will have artifactually low C-peptide that does not reflect their underlying beta-cell mass [12].

Indirect Confounders: Renal Function, Obesity, and Timing

Not every distortion comes from a pill. Three non-pharmacologic factors shift C-peptide values as much as most drugs do.

Renal Impairment

Approximately 70% of circulating C-peptide is cleared by the kidneys. An estimated GFR below 60 mL/min/1.73 m² can raise C-peptide by 30 to 50% without any change in insulin secretion [13]. The Endocrine Society clinical practice guideline on hypoglycemia recommends interpreting C-peptide in the context of renal function and using the C-peptide:creatinine ratio when GFR is impaired [3]. Drugs that worsen renal function (NSAIDs taken chronically, calcineurin inhibitors, high-dose aminoglycosides) can therefore raise C-peptide indirectly.

Obesity and Insulin Resistance

A body mass index above 30 kg/m² is associated with compensatory hyperinsulinemia. Fasting C-peptide values of 4 to 6 ng/mL are common in patients with metabolic syndrome, even without diabetes [14]. Thiazolidinediones (pioglitazone, rosiglitazone) improve insulin sensitivity and may lower C-peptide over months as the compensatory drive decreases. Metformin has a similar but smaller effect: a Diabetes Prevention Program analysis showed modest C-peptide reductions over three years in pre-diabetic participants on metformin 850 mg twice daily compared to placebo [15].

Fasting State and Sample Timing

A non-fasting sample drawn two hours after a carbohydrate-rich meal can yield a C-peptide of 5 to 8 ng/mL in a metabolically healthy person. That same person fasting will measure 1.0 to 2.5 ng/mL. The fed-versus-fasted difference dwarfs most drug effects, yet it is the most frequently omitted detail on lab requisitions.

A Clinical Decision Framework for Interpreting C-Peptide on Medications

The table below organizes the most common confounders by direction of effect, magnitude, and recommended action.

| Drug or Factor | Direction | Estimated Magnitude | Action Before Drawing C-Peptide | |---|---|---|---| | Sulfonylureas (glyburide, glimepiride, glipizide) | ↑ | +25 to 40% | Hold 24 to 48 h if clinically safe; always order sulfonylurea screen | | Meglitinides (repaglinide, nateglinide) | ↑ | +20 to 30% | Hold morning dose; draw fasting before next dose | | GLP-1 agonists (semaglutide, liraglutide, tirzepatide) | ↑ | +10 to 30% | Note on requisition; no practical hold for weekly formulations | | DPP-4 inhibitors (sitagliptin, saxagliptin) | ↑ | +8 to 15% | Note on requisition; hold is optional for borderline cases | | Corticosteroids (prednisone, dexamethasone) | ↑ | +15 to 25% | Defer testing until 2 to 4 weeks after course completion if possible | | Exogenous insulin (all formulations) | ↓ | Variable, can suppress to <0.5 ng/mL | Consider glucagon stimulation test or supervised insulin hold | | Octreotide / lanreotide | ↓ | −40 to 60% | Document dose and timing; interpret with endocrinology input | | Diazoxide | ↓ | −30 to 50% | Recognize suppression is therapeutic; do not interpret as beta-cell failure | | Renal impairment (eGFR <60) | ↑ | +30 to 50% | Use C-peptide:creatinine ratio | | Metformin | ↓ (modest) | −5 to 10% over months | No hold needed; effect is small |

How to Prepare for an Accurate C-Peptide Draw

Clinicians and patients can minimize drug-related distortion by following a short checklist before the blood draw.

For Clinicians

List every glucose-lowering medication, corticosteroid, and somatostatin analog on the lab requisition. Include the dose and timing of the last dose. If the test is ordered to evaluate hypoglycemia, add a sulfonylurea and meglitinide screen to the same sample. For patients on exogenous insulin where residual function is the question, a mixed-meal tolerance test or glucagon stimulation test (1 mg IV glucagon with C-peptide measured at 0 and 6 minutes) is more reliable than a random fasting draw [10].

For Patients

Fast for 8 to 12 hours. Water is fine. Take your morning medications after the blood draw unless your physician instructs otherwise. If you use a short-acting insulin (lispro, aspart), your doctor may ask you to skip the pre-breakfast dose. Do not skip long-acting insulin (glargine, degludec) without explicit guidance, because the risk of hyperglycemia usually outweighs the interpretive benefit.

Special Populations

Pregnant patients have physiologically higher C-peptide levels in the second and third trimesters due to increasing insulin resistance. Post-bariatric surgery patients may show exaggerated postprandial C-peptide spikes because of rapid gastric emptying and accelerated incretin release [16]. Neither of these is a "drug" interaction, but both are common enough to flag.

When C-Peptide Results Require Retesting

A single unexpected result does not establish a diagnosis. The American Association of Clinical Endocrinology recommends repeating the test under standardized conditions when the initial value conflicts with the clinical picture [17]. Specific scenarios where a retest is warranted:

A fasting C-peptide below 0.6 ng/mL in a patient with clinical type 2 diabetes who is on exogenous insulin. The low value may reflect suppression, not autoimmune destruction.

A fasting C-peptide above 3.5 ng/mL in a lean patient with an HbA1c of 5.4%. The elevation may stem from recent corticosteroid use or unrecognized renal impairment.

Any C-peptide drawn within 24 hours of a sulfonylurea dose during a hypoglycemia workup. The result cannot reliably distinguish endogenous hyperinsulinism from drug effect.

C-Peptide Beyond Diagnosis: Monitoring Beta-Cell Decline

Serial C-peptide measurements track the pace of beta-cell loss in type 1 diabetes. The TrialNet Pathway to Prevention study showed that participants who maintained a stimulated C-peptide above 0.2 nmol/L had a 50% lower risk of severe hypoglycemia over five years compared to those below that threshold [18]. For patients with type 2 diabetes on multiple glucose-lowering drugs, trending C-peptide every 12 to 18 months can signal when oral agents are failing and insulin initiation is approaching. The key is consistency: same fasting duration, same medication hold protocol, same assay.

The ADA Standards of Care 2025 recommend measuring C-peptide when the diabetes type is uncertain, when autoantibody results are ambiguous, and when treatment response does not match the presumed diagnosis [2]. Repeat the test with a documented medication list and fasting state every time.